The purpose of the present studies was to assess the immune response induced by recombinant MASH2 protein formulated with the proprietary GSK AS15 immunostimulant (recMASH2+AS15) and evaluate its ability to control the growth of MASH2-expressing transplantable tumors in CB6F1 mice and spontaneous colon adenomas in Apc+/Min-FCCC mice. This evidence concerns the gene ASCL2 and colon adenoma.